CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1989; 39:105-114
doi: 10.3322/canjclin.39.2.105
© 1989 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Souba, W. W.
Right arrow Articles by Copeland, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Souba, W. W.
Right arrow Articles by Copeland, E. M., III

CA: A Cancer Journal for Clinicians, Vol 39, 105-114, Copyright © 1989 by American Cancer Society

Hyperalimentation in Cancer

Wiley W. Souba MD, ScD1 and Edward M. Copeland III MD2

1 Assistant Professor of Surgery and Biochemistry and Director of Surgical Metabolism at the University of Florida College of Medicine in Gainesville, Florida.
2 Edward R. Woodward Professor and Chairman of the Department of Surgery at the University of Florida College of Medicine in Gainesville, Florida.

When response rates to antineoplastic therapy are good and the associated nutritional morbidity is high, TPN is recommended when the gastrointestinal tract is unavailable for use. Patients should not be denied adequate cancer treatment because of the fear of complications secondary to malnutrition. On the other hand, prolongation of pain and suffering for the terminally ill cancer patient is obviously not an indication for TPN. Appropriate clinical judgment is required in proper selection of the TPN candidate. Malnutrition is almost always a prerequisite, as is failure of the gastrointestinal tract.

Therapies designed to direct nutritional support to preferentially benefit the host and "starve" the tumor have had only limited short-term success in animal models. The use of diets that are glutamine- and arginine-supplemented are only now being examined in animal experiments. Since TPN allows total and complete control of exogenous nutrients, it should be used to explore alternative therapies in the form of nutrient composition. For example, if tumors are preferential glutamine utilizers, then TPN-enriched solutions might be employed to increase the number of cells in a phase of mitosis that makes them more susceptible to attack by cell-cycle specific chemotherapeutic agents. Stimulation of tumor growth by TPN in patients is not scientifically documented. Only anecdotal reports appear in the literature. Thousands of cancer patients worldwide have received TPN. Were stimulation of tumor growth to be a major problem with TPN solutions as currently formulated, it should be known by now.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by American Cancer Society.